SOLARA Stock Overview
Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Solara Active Pharma Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹686.75 |
| 52 Week High | ₹882.80 |
| 52 Week Low | ₹323.30 |
| Beta | 1.2 |
| 1 Month Change | -9.81% |
| 3 Month Change | -8.37% |
| 1 Year Change | 108.71% |
| 3 Year Change | -30.87% |
| 5 Year Change | 53.05% |
| Change since IPO | 172.79% |
Recent News & Updates
Recent updates
The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More
Sep 13
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce
Jul 20Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
May 11Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump
Apr 19Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Mar 13Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely
Feb 23Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce
Jan 04Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price
May 12Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
Nov 08Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Sep 30Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?
Aug 03Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt
Jun 19Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts
Feb 17A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
Dec 21Shareholder Returns
| SOLARA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -7.6% | 1.8% | -2.1% |
| 1Y | 108.7% | 43.7% | 22.5% |
Return vs Industry: SOLARA exceeded the Indian Pharmaceuticals industry which returned 43.7% over the past year.
Return vs Market: SOLARA exceeded the Indian Market which returned 22.5% over the past year.
Price Volatility
| SOLARA volatility | |
|---|---|
| SOLARA Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: SOLARA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SOLARA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 2,156 | Poorvank Purohit | www.solara.co.in |
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antifungal, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support.
Solara Active Pharma Sciences Limited Fundamentals Summary
| SOLARA fundamental statistics | |
|---|---|
| Market cap | ₹33.00b |
| Earnings (TTM) | -₹5.36b |
| Revenue (TTM) | ₹12.22b |
2.7x
P/S Ratio-6.2x
P/E RatioIs SOLARA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOLARA income statement (TTM) | |
|---|---|
| Revenue | ₹12.22b |
| Cost of Revenue | ₹8.07b |
| Gross Profit | ₹4.15b |
| Other Expenses | ₹9.51b |
| Earnings | -₹5.36b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -111.57 |
| Gross Margin | 33.97% |
| Net Profit Margin | -43.88% |
| Debt/Equity Ratio | 75.3% |
How did SOLARA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 20:00 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Solara Active Pharma Sciences Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |
| Rishabh Kale | Indsec Securities & Finance Ltd. |